Informations générales (source: ClinicalTrials.gov)
Medical and Economic Evaluation of an External Beam Radiotherapy Combined With a Brachytherapy Boost Compared With an Exclusive External Beam Radiotherapy for Intermediate-risk Prostate Cancer (GETUGP05)
Interventional
N/A
Hospices Civils de Lyon (Voir sur ClinicalTrials)
juin 2013
juin 2021
29 juin 2024
The aim of the present phase III study is two-folded: 1) to show a superiority of
external beam radiotherapy combined with a brachytherapy boost versus exclusive external
beam radiotherapy and 2) to evaluate the economic impact of each treatment.
The study includes 33 cancer centres, the inclusion time is of 2 years and the follow-up
is of 5 years.
Etablissements
Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
CLCC INSTITUT CURIE | 10/04/2025 13:12:21 | Contacter | |||
CLCC INSTITUT GUSTAVE ROUSSY | Alberto BOSSI | 08/01/2024 09:12:51 | Contacter | ||
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
AP-HP - Hôpital Europeen Georges Pompidou | Martin HOUSSET, MD | Contact (sur clinicalTrials) | |||
CH RIVES DE SEINE SITE NEUILLY S/SEINE | Laurent CHAUVEINC, MD | Contact (sur clinicalTrials) | |||
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
Centre Antoine Lacassagne - 06189 - Nice - France | Jean-Michel HANNOUN LEVI, MD | Contact (sur clinicalTrials) | |||
Centre Eugène Marquis - 50420 - Rennes - France | Renaud DE CREVOISIER, MD | Contact (sur clinicalTrials) | |||
Centre Francois Baclesse - 14076 - Caen - France | Marlon SILVA, MD | Contact (sur clinicalTrials) | |||
Centre Georges François Leclerc - 21079 - Dijon - France | Gilles CREHANGE, MD | Contact (sur clinicalTrials) | |||
Centre Henry Becquerel - 76038 - Rouen - France | Ahmed BENYOUCEF, MD | Contact (sur clinicalTrials) | |||
Centre Paul Strauss - 67065 - Strasbourg - France | Marius POP, MD | Contact (sur clinicalTrials) | |||
Centre Regional de Lutte Contre Le Cancer Rhone-Alpes Centre Leon Berard - 69373 - Lyon - France | Pascal POMMIER, MD | Contact (sur clinicalTrials) | |||
CHRU Morvan - 29609 - Brest - France | Jean-Pierre MALHAIRE, MD | Contact (sur clinicalTrials) | |||
CHU Jean MINJOZ - 25030 - Besançon - France | Yasser HAMMOUD, MD | Contact (sur clinicalTrials) | |||
CHU Poitiers - 86021 - Poitiers - France | Stéphane GUERIF, MD | Contact (sur clinicalTrials) | |||
Clinique Claude Bernard - 81000 - Albi - France | Laurent VOTRON, MD | Contact (sur clinicalTrials) | |||
Clinique du TONKIN - 69626 - Villeurbanne - France | ARDIET Jean-Michel, MD | Contact (sur clinicalTrials) | |||
Hopital de la Tronche - 38043 - Grenoble - France | Michel BOLLA, MD | Contact (sur clinicalTrials) | |||
Hopital Saint-Louis - 75475 - Paris - France | Christophe HENNEQUIN, MD | Contact (sur clinicalTrials) | |||
Hospices Civils de Lyon - 69495 - Pierre-Bénite - France | Olivier CHAPET, MD | Contact (sur clinicalTrials) | |||
Institut Claudius Regaud - 31052 - Toulouse - France | BACHAUD Jean-Marc, MD | Contact (sur clinicalTrials) | |||
Institut de Cancerologie de Lorraine Alexis Vautrin - 54519 - Nancy - France | Didier PEIFFERT, MD | Contact (sur clinicalTrials) | |||
Institut Jean Godinot, - 51056 - Reims - France | Tan Dat NGUYEN, MD | Contact (sur clinicalTrials) | |||
Polyclinique Courlancy - 51057 - Reims - France | Frédéric MALLET, MD | Contact (sur clinicalTrials) | |||
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
Centre d'oncologie et de radiothérapie Mâcon - 71031 - Macon - France | Fabrice LORCHEL, MD | Contact (sur clinicalTrials) | |||
Centre Val D'Aurelle - 34298 - Montpellier - France | Carmen LLACER MOSCARDO, MD | Contact (sur clinicalTrials) | |||
Clinique Tivoli - 33000 - Bordeaux - France | Nathalie BONICHON-LAMICHHANE, MD | Contact (sur clinicalTrials) | |||
Institut Cancérologique de la Loire - 42270 - Saint-priest En Jarez - France | Guy DE LAROCHE, MD | Contact (sur clinicalTrials) | |||
Institut Paoli Calmette - 13273 - Marseille - France | Naji SALEM, MD | Contact (sur clinicalTrials) |
Critères
Homme
Inclusion Criteria:
- age between 18 and 80 years;
- life expectancy of greater than 10 years;
- prostate adenocarcinoma histologically proven;
- prostate cancer has to be of intermediate-risk based on at least one of the three
following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7
and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status
ECOG 0-2.
- the patient has to be the beneficiary of the social security system (order n°
2006-477 from April 26th 2006);
- the signed consent form.
- age between 18 and 80 years;
- life expectancy of greater than 10 years;
- prostate adenocarcinoma histologically proven;
- prostate cancer has to be of intermediate-risk based on at least one of the three
following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7
and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status
ECOG 0-2.
- the patient has to be the beneficiary of the social security system (order n°
2006-477 from April 26th 2006);
- the signed consent form.
- PSA level > 20;
- Gleason > 7;
- clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A
won't be an exclusion criterion);
- prostate volume > 60 cc;
- pelvic lymph nodes involvement at dissection or imaging (ADP > 1.5 cm);
- concurrent hormone therapy;
- the presence of distant metastasis (M1);
- history of abdominal or pelvic irradiation;
- history of prostate resection in the previous 6 months and/or not allowing the
implantation of markers;
- history of uncontrolled cancer and/or treated since less than 5 years (excepting the
basal-cell carcinoma);
- urinary discomfort with an IPSS (International Prostate Symptom Score) > 15 (without
alpha-blocking);
- inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;
- other undergoing study that may interfere with the present study;
- patient under legal protection measure.